TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15970035
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of garlic paste for 14 days
Study: 15970035
Drug: Clotrimazole solution
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole solution
Study: 12520172
Drug: Regular tablets
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular tablets
Study: 10754455
Drug: VML 295
Approvals — FDA: no, EMA: no, PMDA: no
Description: VML 295 at 200 mg twice daily
Study: 10754455
Drug: VML 295
Approvals — FDA: no, EMA: no, PMDA: no
Description: VML 295 at 200 mg once daily
Study: 8862229
Drug: Carvedilol (C)
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol (C) (25 mg)
Study: 1636469
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment program
Study: 24925350
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment with amoxicillin‐omeprazole
Study: 20333738
Drug: BoNT/A treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A treatment after diode laser hair removal
Study: 20333738
Drug: BoNT/A treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A treatment without diode laser hair removal
Study: 20117244
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with certolizumab pegol (400 mg every 4 weeks)
Study: 20117244
Drug: Drug-interruption (placebo)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-interruption (placebo)
Study: 10578479
Drug: Soy beverage
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy beverage containing 20 g of protein and 38 mg of total isoflavones
Study: 6313596
Drug: Acyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (500 mg/m2/dose three times daily for 7 days)
Study: 6313596
Drug: Vidarabine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine (10 mg/kg/day for 5 days)
Study: 6313596
Drug: Acyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (500 mg/m2/dose infused over one hour three times daily for 7 days)
Study: 24552979
Drug: Monthly minodronate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly minodronate (50 mg)
Study: 24552979
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate (35 mg)
Study: 22377800
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone administration (25-50 mg at 16:00 and 20:00 h)
Study: 17255295
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy before cytokine therapy
Study: 17255295
Drug: Targeted agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted agents for advanced renal cell carcinoma
Study: 15356779
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily for 14 days
Study: 15194131
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily for 3 days
Study: 31468249
Drug: CBT (Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT (Cognitive-Behavioral Therapy)
Study: 31468249
Drug: COPE-CBT (Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE-CBT (Cognitive-Behavioral Therapy)
Study: 18838477
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg daily
Study: 18001721
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg/d orally; group A)
Study: 18001721
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet per d; group B)
Study: 12579104
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (24.34 mEq or 3 g in 100 mL saline solution administered over 2 hours preoperatively, perioperatively, and on postoperative days 0, 1, 2, and 3)
Study: 12579104
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (100 mL administered according to the same schedule as treatment group)
Study: 9523374
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral baclofen administered for 14 days
Study: 793842
Drug: Sodium valproate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate, 400 mg
Study: 793842
Drug: Phenobarbital, 60
Normalized name: Phenobarbital, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital, 60 mg
Study: 793842
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate and phenobarbital in combination
Study: 26843724
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of instant coffee divided into three portions right after removing the nasogastric tube, first postoperative day
Study: 26843724
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of tea
Study: 26843724
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of instant coffee
Study: 24075659
Drug: Moderate force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate force (50-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Study: 24075659
Drug: Severe force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Severe force (300-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Study: 16460338
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (0.75% ropivacaine, 1.8 ml)
Study: 16460338
Drug: Ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine + epinephrine (1.8 ml)
Study: 15690112
Drug: Preparation stage
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation stage of change
Study: 9032501
Drug: 3 month
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 month rehabilitation programme including drug treatment
Study: 9032501
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period of drug treatment only
Study: 8320490
Drug: Intravenous deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deferoxamine (DFO) at 180 mg/kg/day
Study: 8320490
Drug: Intravenous deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deferoxamine (DFO) at 150 mg/kg/day for 3 months
Study: 26004980
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment adherence at six months assessment
Study: 26004980
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment adherence at twelve months assessment
Study: 17893603
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: basiliximab, TAC (0.05 mg/kg twice daily) plus MMF (1 g twice daily)
Study: 17893603
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Thymoglobulin, CsA (4 mg/kg twice daily) plus azathioprine (1.5 mg/kg once daily)
Study: 17893603
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: basiliximab, CsA (2 mg/kg twice daily) plus MMF (1 g twice daily)
Study: 8067552
Drug: ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.15 mg/kg intravenously
Study: 8067552
Drug: metoclopramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.25 mg/kg intravenously
Study: 8067552
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 0.3 mL/kg (Control)
Study: 3054622
Drug: Maprotiline (116.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (116.75 mg/day)
Study: 3054622
Drug: Chlorimipramine (116.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (116.25 mg/day)
Study: 31155764
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with prophylactic protocol and monitoring (enzyme declogging kits administered every 7 days for 4 weeks)
Study: 28609319
Drug: methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 20 mg
Study: 28609319
Drug: methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 40 mg
Study: 28609319
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone acetonide 20 mg
Study: 28609319
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone acetonide 40 mg
Study: 28739492
Drug: Citalopram (30±5.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30±5.8 mg/d)
Study: 28739492
Drug: Quetiapine (94.0±40.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (94.0±40.4 mg/d)
Study: 28739492
Drug: Olanzapine (5.2±1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5.2±1.6 mg/d)
Study: 24038103
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (specifics not provided)
Study: 24038103
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (implied control group)
Study: 16565560
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) treatment, subcutaneously injected once a day for 10 days at a low dose.
Study: 16565560
Drug: Non-G-CSF control
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-G-CSF control group.
Study: 12603186
Drug: Fluticasone 100
Normalized name: FLUTICASONE 100MCG/BLSTR PO INH ROTADISK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 100 microg daily
Study: 12603186
Drug: Fluticasone 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 1000 microg daily
Study: 12603186
Drug: Fluticasone 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 2000 microg daily
Study: 10926069
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intra‐articularly (group 1)
Study: 10926069
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine + 150 microg clonidine intra‐articularly (group 3)
Study: 24140033
Drug: Prolutex (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolutex (25 mg subcutaneously daily)
Study: 24140033
Drug: Crinone (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone (90 mg 8% gel daily)
Study: 22987458
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 153 kPa (1.5 ATA)
Study: 17414047
Drug: Valacyclovir (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1,000 mg/d for 5 days) plus prednisolone (VP)
Study: 11434406
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum extract WS5572 (300 mg t.i.d.)
Study: 8435016
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 micrograms twice a day via a spacer
Study: 8435016
Drug: Budesonide 1600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 micrograms twice a day via a spacer and facemask
Study: 29717032
Drug: Tanezumab (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (pooled all treatment doses)
Study: 29717032
Drug: Composite outcomes
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite outcomes (including WOMAC pain and rescue medication use)
Study: 24876261
Drug: Intravenous tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue‐type plasminogen activator (tPA) followed by endovascular therapy
Study: 24876261
Drug: Intravenous tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue‐type plasminogen activator (tPA) alone
Study: 24876261
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with routine use of general anesthesia
Study: 24876261
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy without routine use of general anesthesia
Study: 23865696
Drug: Gonadotropin initiation
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin initiation 3 weeks after GnRHa administration (Group A)
Study: 23865696
Drug: Gonadotropin initiation
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin initiation 2 weeks after GnRHa administration (Group B)
Study: 20528810
Drug: Pre-cessation nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-cessation nicotine patches and/or gum for 2 weeks prior to quit day
Study: 18837607
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help treatments
Study: 16652426
Drug: Intraarticular hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronic acid (HA) injections (20 mg/ml, 2 ml) administered once weekly for 3 weeks
Study: 16652426
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injections administered once weekly for 3 weeks
Study: 10750292
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) after laparoscopic hysterectomy (LH) and/or bilateral salpingo‐oophorectomy (BSO)
Study: 10750292
Drug: No estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estrogen replacement therapy (control group)
Study: 1424415
Drug: Single-dose sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sotalol (320 mg)
Study: 1424415
Drug: Repeated sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated sotalol administration
Study: 21824124
Drug: Laser dermabrasion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser dermabrasion followed by hydrocortisone 17-butyrate cream and narrowband UVB treatment
Study: 21824124
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids and UVB alone
Study: 21824124
Drug: UVB +
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVB + steroids alone group
Study: 20216113
Drug: Computer-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosing (MAP-BE)
Study: 15695140
Drug: Intravenous monteplase
Normalized name: Monteplase
DrugBank: Monteplase (DB12726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous monteplase followed by PCI
Study: 11838852
Drug: Topical ice
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ice therapy, oral prednisone 30 mg PO tapered to 0 over 6 days, and colchicine 0.6 mg/day
Study: 11838852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same regimen without ice therapy
Study: 11838852
Drug: Topical ice
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ice therapy
Study: 10354080
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) ointment 0.005% (g/g)
Study: 10354080
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) ointment
Study: 2144866
Drug: Recombinant vaccine,
Normalized name: ebola (Zaire) recombinant vaccine, live, vero cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine, 10 micrograms in 1 ml intramuscularly
Study: 2144866
Drug: Plasma-derived vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine, 2 micrograms in 0.1 ml intradermally
Study: 2144866
Drug: Recombinant vaccine,
Normalized name: ebola (Zaire) recombinant vaccine, live, vero cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine, 1 microgram in 0.1 ml intradermally
Study: 6137116
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists and pirenzepine
Study: 17702837
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of [(13)C]bicarbonate during exercise at 45% Vo(2peak)
Study: 17702837
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of [(13)C]bicarbonate during exercise at 65% Vo(2peak)
Study: 8970411
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (0.625 mg/day conjugated estrogens or 2 mg/day estradiol)
Study: 1455880
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (cisplatin and bleomycin) and surgery
Study: 1455880
Drug: Pre-operative chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative chemotherapy, radiotherapy, and surgery
Study: 3549312
Drug: Metoprolol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-200 mg daily)
Study: 6380905
Drug: Methyldopa (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500-1000 mg daily)
Study: 18563389
Drug: Half-molar sodium-lactate
Normalized name: SODIUM LACTATE 1/6 MOLAR INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-molar sodium-lactate (HL) solution, 10 ml kg BW(‐1) over 12 hours
Study: 18563389
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate (RL) solution, 30 ml kg BW(‐1) over 12 hours
Study: 10907144
Drug: Older couples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older couples presenting for conjoint therapy
Study: 10907144
Drug: Younger couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger couples presenting for conjoint therapy
Study: 1535447
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.5 mg nebulized)
Study: 6146861
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 80 mg/m2 on days 1‐14, intravenous methotrexate 32 mg/m2 on days 1 and 8, and intravenous fluorouracil 480 mg/m2 on days 1 and 8 (CMF), repeated every 28 days for twelve cycles.
Study: 28364419
Drug: Modafinil treatment
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil treatment during abstinence
Study: 27185725
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg IV infusion
Study: 27185725
Drug: Labetalol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 0.25 mg/kg IV
Study: 27185725
Drug: Saline 10
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 10 mL IV
Study: 21971575
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg orally, once weekly
Study: 21971575
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg orally once daily
Study: 8339624
Drug: Hydrocortisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (10 mg/kg)
Study: 3789327
Drug: Terbutaline slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline slow-release tablets (Bricanyl Depot), 5 mg twice daily
Study: 3789327
Drug: Terbutaline ordinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline ordinary tablets (Bricanyl), 2.5 mg three times daily
Study: 31469776
Drug: AS04-adjuvanted HPV-16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-adjuvanted HPV-16/18 vaccine (2-dose schedule)
Study: 26907917
Drug: Passive-scattering proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive-scattering proton therapy (PT)
Study: 24519012
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg of alcohol
Study: 19393843
Drug: BUP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BUP infusion (0.4 microg/kg/h) + BUP boluses (0.15 microg/kg)
Study: 19393843
Drug: MO infusion
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO infusion (10 microg/kg/h) + MO boluses (5 microg/kg)
Study: 19393843
Drug: BUP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BUP infusion (0.4 microg/kg/h) + MO boluses (5 microg/kg)